Novel translational therapeutic strategy by sequencing primary liver cancer genomes

What is it about?

Prognosis of primary liver cancer (PLC) remains poor due to resistance to available therapeutics. Based on these limitations, emerging research is focused on cell origins, molecular classification and tumorigenesis, as well as tumor heterogeneity, metastasis and therapeutic resistance.

Featured Image

Why is it important?

The rapid progress and validity of next-generation sequencing (NGS) to identify genetic and genomic heterogeneity, as well as genome-wide mutational landscape, have contributed to our understanding of the molecular mechanisms that underline therapeutic resistance and relapse.

Perspectives